Loading....

Diplomat Pharmacy has begun filling prescriptions for Kevzara (sarilumab) for patients with moderate to severe rheumatoid arthritis (RA). The announcement comes after the U.S. Food and Drug Administration approving the therapy in May. The agency authorized Kevzara for adults with RA who failed to responded to, or were unable to tolerate, disease-modifying antirheumatic drugs (DMARDs) such as methotrexate […]

Active rheumatoid arthritis (RA) patients whose response to methotrexate (MTX) therapy was insufficient showed improvement when MTX was combined with filgotinib, an investigational JAK–1 inhibitor, according to results of a Phase 2b clinical trial. The study titled, “Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis […]

The European Medicines Agency (EMA) has accepted a marketing authorization application from generic pharmaceuticals developer Sandoz for the review of biosimilars for AbbVie’s Humira (adalimumab) and Janssen’s Remicade (infliximab), used in the treatment of autoimmune diseases. Remicade is widely used for rheumatoid arthritis (RA) therapy. Biosimilars are biopharmaceutical drugs that have similar properties to other licensed therapies. Sandoz announced the […]

Results of a recent study showed that biological therapy regimens, such as Enbrel (etanercept), Humira (adalimumab), ‎Remicade (infliximab), ‎Simponi (golimumab), or ‎Cimzia (certolizumab), are less cost-effective compared to DMARD combination in triple therapy with ‎Azulfidine (sulfasalazine), ‎Plaquenil (hydroxychloroquine), and ‎Trexall (methotrexate) in the treatment of rheumatoid arthritis (RA). Importantly, this triple therapy also was found to be […]